 |
Peregrine PS-Targeting Antibodies Show Broad Potential to Image Tumors and Assess Cancer Therapy Response
Sep 12, 2011
|
19.5 KB |
|
| |
TUSTIN, CA -- (MARKET WIRE) -- 09/12/11 --
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced that new data from its phosphatidylserine (PS)-targeting tumor imaging studies were presented at ...
|
|
Peregrine Pharmaceuticals Reports First Quarter Fiscal Year 2012 Financial Results and Recent Developments
Sep 9, 2011
|
27.9 KB |
|
| |
TUSTIN, CA -- (MARKET WIRE) -- 09/09/11 --
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced financial results for the first quarter of fiscal year (FY) 2012 ended July 31, 2011 and provided...
|
|
Peregrine Completes Patient Enrollment in Randomized Phase II Trial for Bavituximab in Front-Line Non-Small Cell Lung Cancer
Sep 8, 2011
|
19.9 KB |
|
| |
TUSTIN, CA -- (MARKET WIRE) -- 09/08/11 --
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced the completion of enrollment and randomization of 86 patients with previously untreated non-small...
|
|
Peregrine to Report First Quarter Fiscal Year 2012 Financial Results Before Market on September 9, 2011
Sep 2, 2011
|
13.8 KB |
|
| |
TUSTIN, CA -- (MARKET WIRE) -- 09/02/11 --
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced that it will report financial results for the first quarter of fiscal year 2012 on September 9, 20...
|
|
Peregrine Prices $7 Million Registered Direct Offering of Common Stock
Sep 2, 2011
|
14.6 KB |
|
| |
TUSTIN, CA -- (MARKET WIRE) -- 09/02/11 --
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced that it has entered into subscription agreements for the sale of an aggregate of 6,252,252 shares...
|
|
Peregrine to Present at Stifel Nicolaus Healthcare Conference September 8, 2011 at 11:30 AM EDT
Sep 1, 2011
|
13.7 KB |
|
| |
TUSTIN, CA -- (MARKET WIRE) -- 09/01/11 --
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced it will present at the 2011 Stifel Nicolaus Healthcare Conference in Boston, Massachusetts on Thu...
|
|
Peregrine Reports Promising 20.7 Month Median Overall Survival From Phase II Advanced Breast Cancer Trial
Aug 24, 2011
|
18.9 KB |
|
| |
TUSTIN, CA -- (MARKET WIRE) -- 08/24/11 --
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced 20.7 month median overall survival (OS) from a prior single-arm Phase II trial evaluating bavitux...
|
|
Peregrine Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2011 Financial Results and Recent Developments
Jul 14, 2011
|
30.3 KB |
|
| |
TUSTIN, CA -- (MARKET WIRE) -- 07/14/11 --
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM),
a clinical-stage biopharmaceutical company developing first-in-class
monoclonal antibodies for the treatment of cancer and viral infections,
today announced financial results for the fourth quarter and fiscal year
(FY) 2011 ended April 30, 201...
|
|
Peregrine to Report Fourth Quarter and Fiscal Year 2011 Financial Results After Market Close on July 14, 2011
Jul 7, 2011
|
13.7 KB |
|
| |
TUSTIN, CA -- (MARKET WIRE) -- 07/07/11 --
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced that it will report financial results for the fourth quarter and fiscal year 2011 on July 14, 201...
|
|
Peregrine Reports Promising 12.4 Month Overall Survival Data From Phase II Trial in Non-Small Cell Lung Cancer
Jun 15, 2011
|
19.1 KB |
|
| |
TUSTIN, CA -- (MARKET WIRE) -- 06/15/11 --
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today reported promising median overall survival (MOS) of 12.4 months from a Phase II clinical trial evaluating b...
|
|
Peregrine Presents Promising Phase II Survival Data in Recurrent GBM With Single Treatment of Cotara at ASCO Annual Meeting
Jun 3, 2011
|
19.8 KB |
|
| |
TUSTIN, CA and CHICAGO, IL -- (MARKET WIRE) -- 06/03/11 --
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today is presenting data from a Phase II trial of Cotara® in recurrent glioblastoma multifor...
|
|
Peregrine Appoints Jeffrey Masten as Vice President, Quality as Company Advances Phase II Clinical Programs
May 31, 2011
|
16.3 KB |
|
| |
TUSTIN, CA -- (MARKET WIRE) -- 05/31/11 --
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced the appointment of Jeffrey L. Masten as Vice President, Quality. In this newly created position, ...
|
|
Keynote Presentation at Leading European Antibody Conference Highlights Immune Reactivation Mechanisms of Bavituximab
May 26, 2011
|
19.4 KB |
|
| |
TUSTIN, CA and BARCELONA, SPAIN -- (MARKET WIRE) -- 05/26/11 --
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced a keynote presentation at the 10th Annual Informa Life Sciences Recombinant ...
|
|
Peregrine Announces Initiation of Phase I/II Prostate Cancer Investigator-Sponsored Trial (IST)
May 25, 2011
|
20.2 KB |
|
| |
TUSTIN, CA and IRVINE, CA -- (MARKET WIRE) -- 05/25/11 --
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced the initiation of an investigator-sponsored trial (IST) for patients with castrati...
|
|
Peregrine Reports Promising Interim Survival Data From Phase II Cotara Recurrent GBM Trial
May 19, 2011
|
20.9 KB |
|
| |
TUSTIN, CA -- (MARKET WIRE) -- 05/19/11 --
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced interim median overall survival of 8.8 months (38 weeks, 40 patients at first relapse) from a Pha...
|
|
Four AACR Presentations Highlight Broad Therapeutic and Diagnostic Potential of Peregrine's First-in-Class PS-Targeting Platform
Apr 6, 2011
|
59.6 KB |
|
| |
TUSTIN, CA and ORLANDO, FL -- (MARKET WIRE) -- 04/06/11 --
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, highlighted data presented at the Annual Meeting of the American Association of Cancer Research (...
|
|
Peregrine's PS-Targeting Antibody Significantly Improves Anti-Tumor Effect of Sorafenib in Models of Advanced Liver Cancer
Apr 5, 2011
|
22.6 KB |
|
| |
TUSTIN, CA and ORLANDO, FL -- (MARKET WIRE) -- 04/05/11 --
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced that its phosphatidylserine (PS)-targeting antibody significantly enhanced the an...
|
|
Peregrine Presents Phase Ib HCV/HIV Data on Single-Agent Bavituximab at EASL
Apr 4, 2011
|
67.3 KB |
|
| |
TUSTIN, CA, and BERLIN, GERMANY -- (MARKET WIRE) -- 04/04/11 --
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced data from its Phase Ib dose escalation safety study of bavituximab in patien...
|
|
Peregrine Pharmaceuticals Reports Third Quarter Fiscal Year 2011 Financial Results and Recent Developments
Mar 11, 2011
|
28.6 KB |
|
| |
TUSTIN, CA -- (MARKET WIRE) -- 03/11/11 --
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a
clinical-stage biopharmaceutical company developing first-in-class
monoclonal antibodies for the treatment of cancer and viral infections,
today announced financial results for the third quarter ended January 31,
2011 for its fiscal year (FY...
|
|
Peregrine Pharmaceuticals to Present at Roth Capital Partners OC Growth Stock Conference
Mar 10, 2011
|
14.8 KB |
|
| |
TUSTIN, CA -- (MARKET WIRE) -- 03/10/11 --
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced it will present at the ROTH Capital Partners 23rd Annual OC Growth Stock Conference in Laguna Nigu...
|
|
|
